282 related articles for article (PubMed ID: 17552440)
1. Anticoagulant effects of low-molecular-weight heparins in healthy cats.
Alwood AJ; Downend AB; Brooks MB; Slensky KA; Fox JA; Simpson SA; Waddell LS; Baumgardner JE; Otto CM
J Vet Intern Med; 2007; 21(3):378-87. PubMed ID: 17552440
[TBL] [Abstract][Full Text] [Related]
2. The effect of a low molecular weight heparin on coagulation parameters in healthy cats.
Vargo CL; Taylor SM; Carr A; Jackson ML
Can J Vet Res; 2009 Apr; 73(2):132-6. PubMed ID: 19436582
[TBL] [Abstract][Full Text] [Related]
3. Use of viscoelastic coagulation testing to monitor low molecular weight heparin administration to healthy horses.
Tennent-Brown BS; Epstein KL; Whelchel DD; Giguère S
J Vet Emerg Crit Care (San Antonio); 2013; 23(3):291-9. PubMed ID: 23656212
[TBL] [Abstract][Full Text] [Related]
4. The effects of unfractionated heparin, low molecular weight heparin and danaparoid on the thromboelastogram (TEG): an in-vitro comparison of standard and heparinase-modified TEGs with conventional coagulation assays.
Coppell JA; Thalheimer U; Zambruni A; Triantos CK; Riddell AF; Burroughs AK; Perry DJ
Blood Coagul Fibrinolysis; 2006 Mar; 17(2):97-104. PubMed ID: 16479191
[TBL] [Abstract][Full Text] [Related]
5. Dose determination of fondaparinux in healthy cats.
Fiakpui NN; Hogan DF; Whittem T; Green HW; Shipley EA; Sederquist KA
Am J Vet Res; 2012 Apr; 73(4):556-61. PubMed ID: 22452504
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic characterization of a medium-molecular-weight heparin in comparison with UFH and LMWH.
Alban S; Welzel D; Hemker HC
Semin Thromb Hemost; 2002 Aug; 28(4):369-78. PubMed ID: 12244484
[TBL] [Abstract][Full Text] [Related]
7. Intestinal absorption of low molecular weight heparin in animals and human subjects.
Nissan A; Ziv E; Kidron M; Bar-On H; Friedman G; Hyam E; Eldor A
Haemostasis; 2000; 30(5):225-32. PubMed ID: 11251329
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic indications of low molecular weight heparins].
Samama MM; Michaut-Paterno F
Arch Mal Coeur Vaiss; 1991 Nov; 84(11 Suppl):1733-43. PubMed ID: 1662941
[TBL] [Abstract][Full Text] [Related]
9. The utility of thromboelastography in monitoring low molecular weight heparin therapy in the coronary care unit.
White H; Sosnowski K; Bird R; Jones M; Solano C
Blood Coagul Fibrinolysis; 2012 Jun; 23(4):304-10. PubMed ID: 22473047
[TBL] [Abstract][Full Text] [Related]
10. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
Wolzt M; Weltermann A; Nieszpaur-Los M; Schneider B; Fassolt A; Lechner K; Eichler HG; Kyrle PA
Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826
[TBL] [Abstract][Full Text] [Related]
11. Dalteparin dose-dependently increases ROTEM(®) thrombelastography parameters only at supratherapeutic anti-factor Xa levels: an in vitro study.
Feuring M; Wehling M; Schultz A
Clin Exp Pharmacol Physiol; 2011 Nov; 38(11):783-6. PubMed ID: 21883380
[TBL] [Abstract][Full Text] [Related]
12. Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers.
Azizi M; Veyssier-Belot C; Alhenc-Gelas M; Chatellier G; Billaud-Mesguish E; Fiessinger JN; Aiach M
Br J Clin Pharmacol; 1995 Dec; 40(6):577-84. PubMed ID: 8703665
[TBL] [Abstract][Full Text] [Related]
13. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin.
Mousa SA; Linhardt R; Francis JL; Amirkhosravi A
Thromb Haemost; 2006 Dec; 96(6):816-21. PubMed ID: 17139378
[TBL] [Abstract][Full Text] [Related]
14. Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa.
Lewis J; Iqbal O; Jeske W; Hoppensteadt D; Siddiqui F; Fareed J
Clin Appl Thromb Hemost; 2022; 28():10760296221099934. PubMed ID: 35535398
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the effects of dalteparin on coagulation variables and determination of a treatment schedule for use in cats.
Schönig JC; Mischke RH
Am J Vet Res; 2016 Jul; 77(7):700-7. PubMed ID: 27347822
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin--a three way cross over study in human volunteers.
Bendetowicz AV; Béguin S; Caplain H; Hemker HC
Thromb Haemost; 1994 Mar; 71(3):305-13. PubMed ID: 8029794
[TBL] [Abstract][Full Text] [Related]
17. A case series of LMWH use in pregnancy: should trough anti-Xa levels guide dosing?
Berresheim M; Wilkie J; Nerenberg KA; Ibrahim Q; Bungard TJ
Thromb Res; 2014 Dec; 134(6):1234-40. PubMed ID: 25450535
[TBL] [Abstract][Full Text] [Related]
18. Inadequate prophylactic effect of low-molecular weight heparin in critically ill COVID-19 patients.
Stattin K; Lipcsey M; Andersson H; Pontén E; Bülow Anderberg S; Gradin A; Larsson A; Lubenow N; von Seth M; Rubertsson S; Hultström M; Frithiof R
J Crit Care; 2020 Dec; 60():249-252. PubMed ID: 32920503
[TBL] [Abstract][Full Text] [Related]
19. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular- weight heparin for the treatment of venous thromboembolism.
Wilson SJ; Wilbur K; Burton E; Anderson DR
Haemostasis; 2001; 31(1):42-8. PubMed ID: 11408748
[TBL] [Abstract][Full Text] [Related]
20. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins.
Brieger D; Dawes J
Thromb Haemost; 1997 Feb; 77(2):317-22. PubMed ID: 9157589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
